<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: To evaluate a strategy combining high-dose 5FU-irinotecan-leucovorin (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>-FOLFIRI) chemotherapy, radiofrequency ablation and surgery in patients with unresectable <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> from <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>PATIENTS AND METHODS: Patients, <z:hpo ids='HP_0000001'>all</z:hpo> presenting <z:chebi fb="15" ids="17659">UDP</z:chebi> glucuronosyl transferase-1A1 (UGT1A1) 6/6 or 6/7 genotype, received <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>-FOLFIRI (with high-dose irinotecan: 260 mg/m(2)), one cycle every two weeks </plain></SENT>
<SENT sid="2" pm="."><plain>The feasibility of local therapy (surgery and/or radiofrequency) was assessed every four cycles </plain></SENT>
<SENT sid="3" pm="."><plain>The objective of therapy was the complete clearance rate of <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: The trial was terminated after inclusion of 18 out of the 40 planned patients due to insufficient recruitment </plain></SENT>
<SENT sid="5" pm="."><plain>The median number of <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> was seven (range=2-30) </plain></SENT>
<SENT sid="6" pm="."><plain>On intention-to-treat analysis, six patients (33.3%) received local treatment of <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> with complete clearance of <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> in each case </plain></SENT>
<SENT sid="7" pm="."><plain>Median progression-free and overall survivals were 15.3 months and 33.7 months, respectively </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION: The assessed strategy is feasible and allows for a complete clearance of <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> in one third of patients, with prolonged survival </plain></SENT>
</text></document>